Phillip Renfroe
Family Medicine · Marion, INNPI 1023105707
Payments from drug & device makers
Across 132 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$754
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$249
- Otsuka America Pharmaceutical, Inc.$244
- Gilead$212
- AstraZeneca$210
- Exact Sciences$170
- plus $618 from 14 others
What the payments were for
- Food & beverage$2,457100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 43 | $754 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $249 |
| Otsuka America Pharmaceutical, Inc. | 13 | $244 |
| Gilead | 11 | $212 |
| AstraZeneca | 11 | $210 |
| Exact Sciences | 8 | $170 |
| Axsome Therapeutics, Inc. | 7 | $159 |
| Novo Nordisk | 4 | $70 |
| Dexcom, Inc. | 3 | $52 |
| Lilly USA, LLC | 3 | $45 |
| Pfizer | 3 | $43 |
| GSK | 2 | $42 |
| Lundbeck LLC | 2 | $36 |
| Amgen | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 2 | $31 |
| Alkermes, Inc. | 1 | $30 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Corium, LLC | 2 | $22 |
| Astellas Pharma US Inc | 1 | $17 |
| Organon | 1 | $12 |
How this compares
$2,457 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $43,031 |
| JardianceEmpagliflozin | 40 | $36,760 |
| TrulicityDulaglutide | 25 | $34,790 |
| EliquisApixaban | 24 | $27,553 |
| FarxigaDapagliflozin Propanediol | 26 | $26,149 |
| Diclofenac Potassium | 15 | $8,611 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $8,090 |
| Levemir FlexpenInsulin Detemir | 25 | $4,266 |
| Aripiprazole | 21 | $3,070 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $2,506 |
| Duloxetine Hcl | 31 | $2,288 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 162 | $2,248 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,984 |
| Levothyroxine Sodium | 87 | $1,572 |
| Omeprazole | 113 | $1,356 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $70 | $43,03134 claims |
| Lilly USA, LLCTrulicity | $45 | $34,79025 claims |
| PfizerEliquis | $43 | $27,55324 claims |
| AstraZenecaFarxiga | $210 | $26,14926 claims |
| GSKBreo Ellipta | $42 | $8,09011 claims |
| AbbVieSynthroid | $754 | $51111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Marion
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.